The underrecognized epilepsy spectrum: The effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production

Journal of Child Neurology

Volumn 24, Issue 7, 2009, Pages 807-815

  Mintz, Mark ^a   LeGoff, Daniel ^a   Scornaienchi, Jean ^a   Brown, Micah ^a,b   Levin Allen, Sarah ^a,c   Mintz, Pnina ^a   Smith, Cathy ^a  

^a Clinical Research Center of New Jersey   (United States)

^b Electrical Geodesics Inc   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

ADHD; Antiepileptic drug; Attention; Benign epilepsy with centrotemporal spikes; Electroencephalography; Levetiracetam; Memory; Neuropsychological function; Rolandic; Seizures

Indexed keywords

ETHOSUXIMIDE; ETIRACETAM; OXCARBAZEPINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; IRRITABILITY; LEARNING DISORDER; LETHARGY; MALE; MENTAL FUNCTION; MORNING DOSAGE; NEUROPSYCHOLOGICAL TEST; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SPIKE WAVE;

ADOLESCENT; ANTICONVULSANTS; ATTENTION; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BRAIN; CHILD; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMANS; LEARNING DISORDERS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PIRACETAM; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67949094439     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808330762     Document Type: Article

References (27)

1. Weglage J., Demsky A., Pietsch M., Kurlemann G. Neuropsychological, intellectual, and behavioral findings in patients with centrotemporal spikes with and without seizures. Dev Med Child Neurol. 1997;39:646-651.
2. Deonna T., Zesiger P., Davidoff V., Maeder M., Mayor C., Roulet E. Benign partial epilepsy of childhood: A longitudinal neuropsychological and EEG study of cognitive function. Dev Med Child Neurol. 2000;42:595-603.
3. Holtmann M., Becker K., Kentner-Figura B., Schmidt MH Increased frequency of rolandic spikes in ADHD children. Epilepsia. 2003;44:1241-1244.
4. Deltour L., Barathon M., Quaglino V., et al. Children with benign epilepsy with centrotemporal spikes (BECTS) show impaired attentional control: Evidence from an attentional capture paradigm. Epileptic Disord. 2007;9:32-38.
5. Datta A., Sinclair DB Benign epilepsy of childhood with rolandic spikes: typical and atypical variants. Pediatr Neurol. 2007;36:141-145.
6. Fonseca LC, Tedrus GM, Pacheco EM Epileptiform EEG discharges in benign childhood epilepsy with centrotemporal spikes: Reactivity and transitory cognitive impairment. Epilepsy Behav. 2007;11:65-70.
7. Stephani U., Carlsson G. The spectrum from BCECTS to LKS: The rolandic EEG trait-impact on cognition. Epilepsia. 2006;47(suppl 2):67-70.
8. Metz-Lutz MN, Filippini M. Neuropsychological findings in rolandic epilepsy and Landau-Kleffner syndrome. Epilepsia. 2006;47(suppl 2):71-75.
9. Deltour L., Quaglino V., De Barathon M., Broca A., Berquin P. Clinical evaluation of attentional processes in children with benign childhood epilepsy with centrotemporal spikes (BCECTS). Epileptic Disord. 2007;9:424-431.
10. Nicolai J., van der Linden I., Arends JB, et al. EEG characteristics related to educational impairments in children with benign childhood epilepsy with centrotemporal spikes. Epilepsia. 2007;48:2093-2100.
11. Wirrell E., Sherman EM, Vanmastrigt R., Hamiwka L. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. J Child Neurol. 2008;23:14-21.
12. Keppra (levetiracetam) [package insert]. Smyrna, GA: UCB, Inc; 2008.
13. Verrotti A., Coppola G., Manco R., et al. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures. Seizure. 2007;16:271-275.
14. Bello-Espinosa LE, Roberts SL Levetiracetam for benign epilepsy of childhood with centrotemporal spikes: Three cases. Seizure. 2003;12:157-159.
15. Coppola G., Franzoni E., Verrotti A., et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): An open-label, parallel group trial. Brain Dev. 2007;29:281-284.
16. Aeby A., Poznanski N., Verheulpen D., Wetzburger C., Van Bogaert P. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: Experience in 12 cases. Epilepsia. 2005;46:1937-1942.
17. Kossoff EH, Los JG, Boatman DF A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy. Epilepsy Behav. 2007;11:514-517.
18. Roid GH, Miller LJ Leiter International Performance Scale-Revised. Wood Dale, IL: Stoelting Co; 1997.
19. Sheslow D., Adams W. Wide Range Assessment of Memory and Learning. Administration and Technical Manual. 2 nd ed. Wilmington, DE: Wide Range, Inc; 2003.
20. Smith DR The Psychological Corporation. Wechsler Individual Achievement Test-Second Edition-Abbreviated. San Antonio: Psychological Corporation, a Harcourt Assessment Company; 2001.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology- Revised (DHEW Publ No. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222.
22. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000;42:281-285.
23. Niespodziany I., Klitgaard H., Margineanu DG Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport. 2003;14:1273-1276.
24. Klitgaard H., Matagne A., Grimee R., Vanneste-Goemaere J., Margineanu DG Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure. 2003;12:92-100.
25. Noyer M., Gillard M., Matagne A., Hénichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137-146.
26. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191-206.
27. Lynch BA, Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861-9866.